Taking stock of the drug industry, from the lab to the medicine chestJune 24, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Alnylam reports positive results for heart drug in pivotal study, likely clearing path to approval The results in the study of the drug, called vutrisiran, are a win for Alnylam after years of efforts to develop a treatment for ATTR-CM. By Elaine Chen STAT+ | Q&A: How Kaiser Permanente tracks and weeds out risky medical devices The network, that includes 40 hospitals, started with a surveillance system to track the outcomes of knee and hip replacements in 2001. By Lizzy Lawrence Opinion: The FDA needs to embrace phage therapy to help fight antimicrobial resistance Phage therapy offers hope for fighting bacteria that have become resistant to antibiotics. The FDA needs to loosen restrictions on its use. By Mark H. Smith Grail STAT+ | Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq After a decade of drama, Grail starts public trading with high hopes for its multi-cancer test but also many issues yet to settle. By Matthew Herper STAT+ | Oral ketamine tablets effective for treating depression, new study finds The new study's findings add to the evidence in support of a regulatory approval for oral ketamine for treatment-resistant depression. By Mohana Ravindranath More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments